Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent.
References:
[1]. Bruno François, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staplococcus aureus: first-in-human trial. Intensive Care Med. 2018 Nov;44(11):1787-1796.
[2]. Philippe Vignon, et al. New Agents in Development for Sepsis: Any Reason for Hope Drugs. 2020 Nov;80(17):1751-1761.